Genpathway Signs Worldwide Agreement With Affymetrix to Provide ChIP-on-Chip Assay Services for New GeneChip(R) Tiling Array Sy
July 26 2006 - 9:30AM
PR Newswire (US)
SAN DIEGO, July 26 /PRNewswire/ -- Genpathway announced today that
it has entered into a worldwide services agreement with Affymetrix,
Inc. (NASDAQ:AFFX) whereby Genpathway will provide ChIP (chromatin
immunoprecipitation)-on-Chip assays, services, and analysis to
pharmaceutical, biotechnology, and academic/institutional
researchers using the new Affymetrix GeneChip(R) Tiling Array
Systems. Affymetrix' recently launched GeneChip Tiling Array
product line enables researchers to identify specific DNA
sequences, including those involved in DNA-protein interactions, at
the whole-genome scale. When applied to ChIP-on- Chip, these new
assays enable comprehensive discovery of binding sites for
transcription factors and co-regulators and the genes they
regulate, as well as genes undergoing active transcription, across
entire genomes. Combining Genpathway's assays and expertise in
chromatin immunoprecipitation with the Affymetrix GeneChip Tiling
Arrays provides pharmaceutical, biotechnology, and
academic/institutional researchers working on a wide range of
genomes a complete ChIP-on-Chip discovery solution. "With this
agreement, researchers in any laboratory can have instant access to
ChIP-on-Chip data generated by Affymetrix GeneChip Tiling Arrays.
This information will enable them to look beyond the known
protein-coding gene sequences to thoroughly study gene structure,
function, and regulation," said Lianne McLean, senior director,
Gene Expression Marketing, Affymetrix. We are confident with
Genpathway's ability to offer the level of performance and
reproducibility our users require." "Interest in and demand for
ChIP-on-Chip assays is expanding rapidly," said Benjamin Monderer,
PhD, CEO of Genpathway. "We are delighted to complete this
agreement with Affymetrix and look forward to providing an
immediate total solution to the current challenges presented by
complicated chromatin immunoprecipitation methods when applied to
tiling arrays." Genpathway offers the following ChIP assay services
using the new Affymetrix tiling arrays: * TranscriptionPath
ChIP-on-Chip/Tiling(TM) * FactorPath ChIP-on-Chip/Tiling(TM) *
FactorPath ChIP-on-Chip/Promoter(TM) About TranscriptionPath(TM)
and FactorPath(TM) Genpathway's transcription-based assays include
TranscriptionPath(TM), which directly analyzes the process of
transcription; and FactorPath(TM), which directly analyzes how
genes are regulated by transcription factors and co-regulating
factors. These two types of direct DNA-based assays may be used
separately or in combination to correlate changes in gene
regulation and transcription. Genpathway offers both types of assay
as a service with four modes of analysis: * ChIP Query Assays:
Quantitative and highly reproducible Q-PCR-based assays * ChIP
Discovery Assays: Assays to find new binding sites and transcribed
regions across the genome * ChIP Expanded Discovery Assays:
Comprehensive genome-wide discovery assays for factor binding sites
and genes * ChIP-on-Chip Assays: Genome-wide assays combining
chromatin immunoprecipitation and Affymetrix GeneChip(R) Tiling
Arrays ABOUT GENPATHWAY (http://www.genpathway.com/) Genpathway,
Inc. is a leading provider of ChIP (chromatin immunoprecipitation)
technologies and services that identify and analyze gene expression
mechanisms and their biological pathways to drive discovery and
testing of novel pharmaceuticals, biomarkers, and diagnostic tests.
Genpathway's assays directly analyze gene transcription, gene
regulation by transcription factors and co-regulators, and the
corresponding genetic pathways. These assays, provided as a service
by Genpathway, are in use by the top pharmaceutical companies as
well as biotechnology, diagnostics, and agriculture companies; and
by academic, government, and nonprofit research institutes
worldwide. ABOUT AFFYMETRIX (http://www.affymetrix.com/) Affymetrix
scientists invented the world's first high-density microarray in
1989 and began selling the first commercial microarray in 1994.
Since then, Affymetrix GeneChip(R) technology has become the
industry standard in molecular biology research. Affymetrix
technology is used by the world's top pharmaceutical, diagnostic
and biotechnology companies as well as leading academic, government
and not-for-profit research institutes. More than 1,400 systems
have been installed around the world and nearly 4,000 peer-reviewed
papers have been published using the technology. Affymetrix'
patented photolithographic manufacturing process provides the most
information capacity available today on an array, enabling
researchers to use a whole-genome approach to analyzing the
relationship between genetics and health. Affymetrix is
headquartered in Santa Clara, Calif., with manufacturing facilities
in Sacramento, Calif., and Bedford, Mass. The company maintains
important sales and marketing operations in Europe and Asia and has
about 1,000 employees worldwide. For more information about
Affymetrix, please visit the company's website at
http://www.affymetrix.com/. Contact: Mary Moynihan M2Friend
Biocommunications 802-951-9600 DATASOURCE: Genpathway, Inc.
CONTACT: Mary Moynihan of M2Friend Biocommunications,
+1-802-951-9600, , for Genpathway, Inc. Web site:
http://www.genpathway.com/ http://www.affymetrix.com/
Copyright
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024